JP2024540226A5 - - Google Patents

Info

Publication number
JP2024540226A5
JP2024540226A5 JP2024525880A JP2024525880A JP2024540226A5 JP 2024540226 A5 JP2024540226 A5 JP 2024540226A5 JP 2024525880 A JP2024525880 A JP 2024525880A JP 2024525880 A JP2024525880 A JP 2024525880A JP 2024540226 A5 JP2024540226 A5 JP 2024540226A5
Authority
JP
Japan
Application number
JP2024525880A
Other languages
Japanese (ja)
Other versions
JP2024540226A (ja
JPWO2023079485A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/060604 external-priority patent/WO2023079485A1/en
Publication of JP2024540226A publication Critical patent/JP2024540226A/ja
Publication of JP2024540226A5 publication Critical patent/JP2024540226A5/ja
Publication of JPWO2023079485A5 publication Critical patent/JPWO2023079485A5/ja
Pending legal-status Critical Current

Links

JP2024525880A 2021-11-03 2022-11-03 抗タウ抗体組成物、投薬形態、及び方法 Pending JP2024540226A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163275045P 2021-11-03 2021-11-03
US63/275,045 2021-11-03
US202163290278P 2021-12-16 2021-12-16
US63/290,278 2021-12-16
US202263316582P 2022-03-04 2022-03-04
US202263316616P 2022-03-04 2022-03-04
US63/316,616 2022-03-04
US63/316,582 2022-03-04
PCT/IB2022/060604 WO2023079485A1 (en) 2021-11-03 2022-11-03 Anti-tau antibody compositions, dosage forms, and methods

Publications (3)

Publication Number Publication Date
JP2024540226A JP2024540226A (ja) 2024-10-31
JP2024540226A5 true JP2024540226A5 (https=) 2025-12-01
JPWO2023079485A5 JPWO2023079485A5 (https=) 2025-12-01

Family

ID=84360026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525880A Pending JP2024540226A (ja) 2021-11-03 2022-11-03 抗タウ抗体組成物、投薬形態、及び方法

Country Status (8)

Country Link
EP (1) EP4426336A1 (https=)
JP (1) JP2024540226A (https=)
KR (1) KR20240118915A (https=)
AU (1) AU2022381556A1 (https=)
CA (1) CA3237660A1 (https=)
MX (1) MX2024005430A (https=)
TW (1) TW202334201A (https=)
WO (1) WO2023079485A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
CN117946264B (zh) * 2024-03-21 2024-06-04 江西赛基生物技术有限公司 一种抗Tau蛋白单克隆抗体及其应用
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074420A2 (en) * 2013-11-27 2016-10-05 Ipierian, Inc. Methods of treating a tauopathy
MA48595A (fr) * 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
EP3697814A1 (en) 2017-10-16 2020-08-26 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20240101654A1 (en) * 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies

Similar Documents

Publication Publication Date Title
JP2024540226A5 (https=)
BR102022025291A2 (https=)
CL2025003842A1 (es) Métodos para el tratamiento y prevención de psoriasis pustulosa generalizada (gpp).
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13167U (https=)
BY13163U (https=)
BY13176U (https=)
BY23963C1 (https=)
CN307044188S (https=)
BY13152U (https=)
BY13135U (https=)